Pharmafile Logo
Pharmafocus logo
Advanced Search

lung cancer

Showing 15 posts of 186 posts found.

AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer

September 9, 2019
Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …

News

Roche celebrates European approval of Tecentriq combo in first-line lung cancer

September 6, 2019
Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq

Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …

News

Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer

September 6, 2019
Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma

Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing …

News
astrazeneca_plaque

AZ’s Tagrisso secures China approval in first-line advanced lung cancer

September 4, 2019
Research and Development, Sales and Marketing AstraZeneca, China, Tagrisso, lung cancer, pharma

AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment …

News
astrazeneca_building_white

AstraZeneca’s Imfinzi flops in advanced treatment-naive non-small cell lung cancer

August 21, 2019
Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in …

News

Roche’s cancer drug Rozlytrek scores double approval from FDA

August 16, 2019
Medical Communications Cancer, Roche, Rozlytrek, lung cancer, oncology

The FDA has approved Roche’s Rozlytrek (entrectinib) as a treatment for adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). …

News
astrazeneca_plaque

AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial

August 9, 2019
Medical Communications AstraZeneca, Cancer, Tagrisso, lung cancer, oncology, pharma

AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung …

News
merck-keytruda

Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund

August 8, 2019
Sales and Marketing CDF, Cancer, MSD, NHS, NICE, UK, keytruda, lung cancer, pharma

MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …

News
headquarters_ingelheim3

Additional data for Boehringer’s Giotrif combo shows strong overall survival benefit in lung cancer sub-population

August 5, 2019
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, giotrif, lung cancer, pharma

German firm Boehringer Ingelheim has released new interim data from a real-world evidence study investigating the efficacy of Giotrif/Gilotrif (afatinib) …

News
images

Roche’s Tecentriq combo recommended in Europe for non-small cell lung cancer

July 29, 2019
Sales and Marketing Cancer, NSCLC, Roche, lung cancer, pharma, tecentriq

Riche’s blockbuster immunotherapy Tecentriq (atezolizumab) is closing in on securing yet another approval after it revealed that the drug was …

News
opdivo_1_1

BMS’ blockbuster Opdivo flies high and falls short in non-small cell lung cancer

July 25, 2019
Research and Development Bristol-Myers Squibb, NSCLC, immuntherapy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …

News
astrazeneca_plaque

AstraZeneca’s Imfinzi gets orphan drug designation from FDA

July 12, 2019
Medical Communications AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC). The …

News

NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer

July 5, 2019
Medical Communications, Sales and Marketing Cancer, NHS, NICE, Pfizer, UK, Vizimpro, lung cancer, pharma

NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a …

News
merck-keytruda

MSD’s Keytruda snatches up first approval in small cell lung cancer

June 19, 2019
Research and Development, Sales and Marketing Cancer, FDA, MSD, US, keytruda, lung cancer, pharma

MSD has revealed that its anti-PD-1 immunotherapy Keytruda (pembrolizumab) has been awarded marketing authorisation from the FDA as a monotherapy …

News
merckentranceweb

Longest follow up trial of Merck’s Keytruda sets new standard for five year survival in lung cancer

June 3, 2019
Sales and Marketing KEYNOTE, MSD, Merck, keytruda, lung cancer

Nearly a quarter of previously untreated lung cancer patients who took Keytruda (Pembrolizumab) were alive after five years, according to …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023